LEVETIRACETAM DEXCEL 750

Country: Israel

Language: English

Source: Ministry of Health

Active ingredient:

LEVETIRACETAM

Available from:

DEXCEL PHARMA TECHNOLOGIES LTD

ATC code:

N03AX14

Pharmaceutical form:

TABLETS

Composition:

LEVETIRACETAM 750 MG

Administration route:

PER OS

Prescription type:

Required

Manufactured by:

DEXCEL LTD, ISRAEL

Therapeutic group:

LEVETIRACETAM

Therapeutic area:

LEVETIRACETAM

Therapeutic indications:

Levetiracetam Dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Dexcel is indicated as adjunctive therapy:• In the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.• In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Authorization date:

2018-03-31